Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.60 |
| ▸ | MMP13 | P45452 | 11/20 | 0.60 |
| ▸ | MMP9 | P14780 | 9/20 | 0.60 |
| ▸ | MMP3 | P08254 | 8/20 | 0.60 |
| ▸ | MMP1 | P03956 | 7/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 3/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329640 | 1.00 | MMP2 (0.60) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL13570499 | 0.86 | MMP2 (0.62) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL4620929 | 0.86 | MMP2 (0.66) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL13570807 | 0.86 | MMP2 (0.62) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL4619626 | 0.86 | MMP2 (0.66) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL11887788 | 0.86 | MMP2 (0.62) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL4621504 | 0.86 | MMP2 (0.66) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL8093833 | 0.84 | SLC1A3 (0.63) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7391079 | 0.84 | KEAP1 (0.62) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7425855 | 0.84 | KEAP1 (0.62) | MMP2MMP13MMP9MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
| EP-0939629-A4 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-0939629-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998003166-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | MMP2 26/4885MMP13 2/4885MMP9 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.